Research & Evidence Base Flashcards
7 cards from real CLT practice questions. Tap to flip, then mark Knew It or Still Learning — missed cards come back until you master them.
Read the first 7 Research & Evidence Base flashcards as text
Which assessment tool was specifically developed to measure insight in individuals with schizophrenia and is commonly used in LEAP-related research?
Answer: Scale to Assess Unawareness of Mental Disorder (SUMD)
The SUMD (Scale to Assess Unawareness of Mental Disorder), developed by Amador and colleagues, directly measures anosognosia across symptom domains in schizophrenia research.
Research on anosognosia prevalence in schizophrenia consistently shows that what approximate percentage of individuals have significant unawareness of their illness?
Answer: 40–50%
Studies estimate that approximately 40–50% of people with schizophrenia have significant anosognosia, making it one of the most common features of the illness.
A study comparing LEAP-trained clinicians versus treatment-as-usual showed the greatest measurable difference in which outcome?
Answer: Medication adherence rates
LEAP research consistently demonstrates its strongest effect on medication adherence, as the approach directly targets the therapeutic alliance barrier posed by poor insight.
The concept of 'reflective listening' in LEAP's evidence base draws most heavily from the randomized controlled trial literature of which parent approach?
Answer: Motivational Interviewing
Reflective listening in LEAP is grounded in Motivational Interviewing (MI), whose RCT evidence base in substance use and health behavior change directly informed LEAP's development.
In neuroimaging studies referenced in anosognosia research, poor illness insight is most consistently associated with dysfunction in which brain region?
Answer: Prefrontal cortex and anterior cingulate
Neuroimaging research links anosognosia to prefrontal cortex and anterior cingulate dysfunction, impairing self-monitoring and error-detection capacities.
Which research design is considered the gold standard for evaluating LEAP's efficacy in improving treatment engagement?
Answer: Randomized controlled trial with blinded outcome assessment
Randomized controlled trials with blinded outcome assessment provide the highest level of evidence for causal claims about LEAP's efficacy.
Early studies on insight deficits in psychosis found that poor insight was a stronger predictor of medication nonadherence than which competing factor?
Answer: Side effect burden
Research demonstrated that insight deficit predicted nonadherence more powerfully than side effect burden, challenging the assumption that medication problems alone drove noncompliance.